MKP Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

MKP Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-6,600	Closed	-$390K	–	14
2016 Q4	$390K	Buy	+6,600	New	+$407K	0.17%	8

Other funds holding XBI

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

MKP Capital Management's XBI Position: Q1 2023 in Review

MKP Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2023, closing a stake of 52,750 shares — an estimated $4.38M sold.

MKP Capital Management first reported a position in XBI in Q4 2016 and held it in 2 quarters. The position peaked at $4.38M in Q4 2022. 713 funds tracked by Wall St. Rank hold XBI as of Q1 2023.

MKP Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2023 after selling out during the quarter.
MKP Capital Management sold 52,750 State Street SPDR S&P Biotech ETF shares in Q1 2023, an estimated $4.38M.
MKP Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and held it in 2 quarters.
MKP Capital Management's State Street SPDR S&P Biotech ETF position peaked at $4.38M in Q4 2022.
713 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2023.

Based on MKP Capital Management's 13F filing for Q1 2023, filed 15 May 2023.